N-Acetyl-Ser-Asp-Lys-Pro是骨髓分泌的一种内源性四肽，是angiotensin-converting enzyme (ACE)的N末端位点的特异性底物。
Cas No.:127103-11-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
N-Acetyl-Ser-Asp-Lys-Pro is an endogenous tetrapeptide secreted by bone marrow, which is a specific substrate for the N-terminal site of angiotensin-converting enzyme (ACE) [1]. N-Acetyl-Ser-Asp-Lys-Pro inhibits hematopoietic stem cells from entering the S phase, participates in the regulation of hematopoietic stem cell proliferation, and can block a stem cell-specific proliferation stimulating factor, selectively acting on quiescent progenitors [2]. N-Acetyl-Ser-Asp-Lys-Pro has been widely used to inhibit the differentiation of hematopoietic stem cells and tissue fibrosis[3].
In vitro, N-Acetyl-Ser-Asp-Lys-Pro treatment (1nM) for 24 hours significantly inhibited the inhibitory effect of S17092 (100μg/ml) on the proliferation of U87-MG cells, and induced Akt phosphorylation[4]. Treatment with 1nM N-Acetyl-Ser-Asp-Lys-Pro for 24 hours significantly inhibited the cell cycle progression of rat cardiac fibroblasts from the G0/G1 phase to the S phase, and led to a decrease in the phosphorylation and nuclear translocation of Smad2[5]. Treatment with 100nM N-Acetyl-Ser-Asp-Lys-Pro for 72 hours significantly inhibited the increase in MMP-2 and MMP-9 protein levels induced by IL-1β in rat cardiac fibroblasts, and reduced collagenase activity[6].
In vivo, N-Acetyl-Ser-Asp-Lys-Pro treatment via daily subcutaneous injection at a dose of 800μg/kg for 3 weeks alleviated proteinuria and renal fibrosis in the hypertensive rat model induced by 5/6 nephrectomy, and improved renal function[7]. Daily subcutaneous injection of 800μg/kg dose of N-Acetyl-Ser-Asp-Lys-Pro was administered for 12 weeks to prevent inflammatory cell infiltration, collagen deposition, downregulation of renin expression and proteinuria in hypertensive mice [8].
References:
[1] Stéphan J P, Melaine N, Ézan E, et al. Source, catabolism and role of the tetrapeptide N-acetyl-ser-asp-lys-Pro within the testis[J]. Journal of Cell Science, 2000, 113(1): 113-121.
[2] Rousseau A, Michaud A, Chauvet M T, et al. The hemoregulatory peptide N-Acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme (∗)[J]. Journal of Biological Chemistry, 1995, 270(8): 3656-3661.
[3] Douglas R G, Ehlers M R, Sturrock E D. Antifibrotic peptide N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP): opportunities for angiotensin-converting enzyme inhibitor design[J]. Clinical & Experimental Pharmacology & Physiology, 2013, 40(8).
[4] Hu P, Li B, Zhang W, et al. AcSDKP regulates cell proliferation through the PI3KCA/Akt signaling pathway[J]. PloS one, 2013, 8(11): e79321.
[5] Pokharel S, Rasoul S, Roks A J M, et al. N-acetyl-Ser-Asp-Lys-Pro inhibits phosphorylation of Smad2 in cardiac fibroblasts[J]. Hypertension, 2002, 40(2): 155-161.
[6] Rhaleb N E, Pokharel S, Sharma U C, et al. N-acetyl-Ser-Asp-Lys-Pro inhibits interleukin-1β-mediated matrix metalloproteinase activation in cardiac fibroblasts[J]. Pflügers Archiv-European Journal of Physiology, 2013, 465(10): 1487-1495.
[7] Liao T D, Yang X P, D'Ambrosio M, et al. N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal injury and dysfunction in hypertensive rats with reduced renal mass: council for high blood pressure research[J]. Hypertension, 2010, 55(2): 459-467.
[8] Rhaleb N E, Pokharel S, Sharma U, et al. Renal protective effects of N-acetyl-Ser-Asp-Lys-Pro in deoxycorticosterone acetate–salt hypertensive mice[J]. Journal of hypertension, 2011, 29(2): 330-338.
N-Acetyl-Ser-Asp-Lys-Pro是骨髓分泌的一种内源性四肽，是angiotensin-converting enzyme (ACE)的N末端位点的特异性底物[1]。N-Acetyl-Ser-Asp-Lys-Pro可抑制造血干细胞进入S期，参与调控造血干细胞增殖，并能阻断一种干细胞特异性增殖刺激因子，选择性地作用于静止期祖细胞[2]。N-Acetyl-Ser-Asp-Lys-Pro已被广泛用于抑制造血干细胞分化和组织纤维化[3]。
在体外，1nM的N-Acetyl-Ser-Asp-Lys-Pro处理U87-MG细胞24小时，显著抑制了S17092对细胞增殖的抑制作用，并诱导了Akt磷酸化[4]。1nM的N-Acetyl-Ser-Asp-Lys-Pro处理大鼠心脏成纤维细胞24小时，显著抑制了细胞周期从G0/G1期向S期的进程，并导致Smad2磷酸化和核转位减少[5]。100nM的N-Acetyl-Ser-Asp-Lys-Pro处理大鼠心脏成纤维细胞72小时，显著抑制了IL-1β诱导的MMP-2和MMP-9蛋白水平升高，并降低了胶原酶活性[6]。
在体内，每日皮下注射800μg/kg剂量的N-Acetyl-Ser-Asp-Lys-Pro，持续3周，减轻了5/6肾切除诱导的高血压大鼠模型中的蛋白尿和肾纤维化，并改善了肾功能[7]。每日皮下注射800μg/kg剂量的N-Acetyl-Ser-Asp-Lys-Pro，持续12周，可预防高血压小鼠的炎症细胞浸润、胶原沉积、肾素表达下调和蛋白尿[8]。
| Cell experiment [1]: | |
Cell lines | Rat cardiac fibroblasts |
Preparation Method | Rat cardiac fibroblasts were cultured at 37°C and 5% CO2 in DMEM medium supplemented with 10% fetal bovine serum (FBS), 1% L-glutamate, 50U/ml penicillin, and 0.1g/l streptomycin. Cells were plated at a density of 1.2×104 cells/ml in a 96-well plate with growth medium for 24h, and then were incubated with the different concentrations of N-Acetyl-Ser-Asp-Lys-Pro (0, 0.01, 0.1, and 1nM) for 24h, analyzed the cell viability. |
Reaction Conditions | 0, 0.01, 0.1, and 1nM; 24h |
Applications | N-Acetyl-Ser-Asp-Lys-Pro treatment significantly inhibited cell viability of Rat cardiac fibroblasts in a concentration-dependent manner. |
| Animal experiment [2]: | |
Animal models | Male Sprague Dawley rats |
Preparation Method | Male Sprague Dawley rats weighing 275 to 300g were housed in an air-conditioned room with a 12h light/dark cycle and received standard laboratory rat chow and tap water. Rats were allowed 7 days to adjust to their new environment. Before all of the surgical procedures, rats were given analgesia (2mg/kg of butorphanol; s.c.) and anesthesia (50mg/kg of sodium pentobarbital; i.p.). Rats were anesthetized and 5/6Nx was performed by unilateral nephrectomy plus ligation of lower and upper renal arterial branches of the contralateral kidney with a 6-0 silk suture. Ligation was deemed successful when two thirds of the kidney turned dark red. The sham-operated group underwent a similar surgical procedure except that the suture around the renal artery was not tightened. An osmotic minipump filled with N-Acetyl-Ser-Asp-Lys-Pro (800μg/kg/day) for 3 weeks or vehicle (0.01M acetic acid saline solution) was implanted s.c. between the shoulder blades. At the end of the research, the kidneys were collected for analysis. |
Dosage form | 800μg/kg/day for 3 weeks; s.c. |
Applications | N-Acetyl-Ser-Asp-Lys-Pro treatment attenuated renal fibrosis and improved the renal function in rats. |
References: | |
| Cas No. | 127103-11-1 | SDF | |
| 别名 | 戈雷拉肽,Ac-SDKP | ||
| Canonical SMILES | Ac-Ser-Asp-Lys-Pro | ||
| 分子式 | C20H33N5O9 | 分子量 | 487.5 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0513 mL | 10.2564 mL | 20.5128 mL |
| 5 mM | 410.3 μL | 2.0513 mL | 4.1026 mL |
| 10 mM | 205.1 μL | 1.0256 mL | 2.0513 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet